CareDx
CDNA
Market cap $1.49B

28.16 USD

-4.00

12.44%

At close Oct 9, 4:00 PM EDT

After hours

28.16

+0.00

0.00%

1 day

-12.44%

5 days

-8.84%

1 month

2.66%

3 months

92.61%

6 months

183.02%

Year to date

135.85%

1 year

336.59%

5 years

6.67%

About: CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre-and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates major revenue from the Testing services.

Employees: 643

Healthcare Medical Laboratories

0

Funds holding %

of 6,740 funds

0

Analysts bullish %

of 5 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

150% more call options, than puts

Call options by funds: $1.5M | Put options by funds: $602K

50% more funds holding in top 10

Funds holding in top 10: 2 [Q1] → 3 (+1) [Q2]

40% more capital invested

Capital invested by funds: $593M [Q1] → $830M (+$238M) [Q2]

32% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 25

6% more funds holding

Funds holding: 145 [Q1] → 153 (+8) [Q2]

5.4% less ownership

Funds ownership: 108.1% [Q1] → 102.7% (-5.4%) [Q2]

12% less repeat investments, than reductions

Existing positions increased: 50 | Existing positions reduced: 57

See Fund Rankings

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$16

43%

downside

Avg. target

$28

1%

upside

High target

$40

42%

upside

5 analyst ratings

4 positive

80%

0 neutral

0%

1 negative

20%

Wells Fargo Brandon Couillard 63% 1-year accuracy 5 / 8 met price target	1%downside $28	Underweight Initiated	27 Aug 2024
BTIG Sung Ji Nam 67% 1-year accuracy 10 / 15 met price target	42%upside $40	Buy Upgraded	19 Aug 2024
Goldman Sachs Matthew Sykes 88% 1-year accuracy 7 / 8 met price target	8%downside $26	Buy Maintained	1 Aug 2024
Craig-Hallum Connor Chamberlain 100% 1-year accuracy 3 / 3 met price target	14%upside $32	Buy Maintained	1 Aug 2024
Goldman Sachs Matthew Sykes 88% 1-year accuracy 7 / 8 met price target	43%downside $16	Buy Maintained	17 Jul 2024

See Analyst Rankings

Financial journalist opinion

Based on 10 articles about CDNA published over the past 30 days

CareDx Appoints Jing Huang Chief Data and AI Officer

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA)- The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced the appointment of Jing Huang Ph.D., in the newly created role of Chief Data and Artificial Intelligence (AI) Officer. Huang will lead key data science initiatives that are a part of the Compa.

CareDx Appoints Jing Huang Chief Data and AI Officer

CareDx to Host Investor Day on October 15, 2024

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced the Company will be hosting an Investor Day on October 15, 2024, in New York City, New York, starting at 8:00 a.m. Eastern Time / 5:00 a.m. Pacific Time. The event will feature presentations.

CareDx to Host Investor Day on October 15, 2024

CareDx Announces Closure of DOJ Investigation with No Finding of Wrongdoing

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the Department of Justice (DOJ) has concluded its investigation into CareDx with no finding of wrongdoing and declined to take any further action. In a Court document unsealed on October.

CareDx Announces Closure of DOJ Investigation with No Finding of Wrongdoing

CareDx Inc (CDNA) Trading 6.16% Higher on Oct 2

Shares of CareDx Inc (CDNA, Financial) surged 6.16% in mid-day trading on Oct 2. The stock reached an intraday high of $32.97, before settling at $32.83, up from its previous close of $30.93.

CareDx Inc (CDNA) Trading 6.16% Higher on Oct 2

CAREDX INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of CareDx, Inc. - CDNA

NEW ORLEANS, LA / ACCESSWIRE / September 30, 2024 / Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq.

CAREDX INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of CareDx, Inc. - CDNA

CareDx Resolves Key Issues: Poised For Growth In Transplant Diagnostics

CDNA has resolved corporate instability and insurance issues, showing potential for sustainable growth with innovative transplant testing services like AlloSure, AlloMap, and HeartCare. CDNA's products are supported by scientific literature and recent Medicare coverage expansions, enhancing their market potential and revenue growth prospects. The appointment of CEO John W. Hanna provides stable leadership and strategic direction for long-term objectives.

CareDx Resolves Key Issues: Poised For Growth In Transplant Diagnostics

SHAREHOLDER ALERT: Morris Kandinov Investigating CareDx, Inc., Puerto Rico Residents Tax-Free Fund, Inc., Puerto Rico Residents Tax-Free Fund VI, Inc., and Tax Free Fund for Puerto Rico Residents, Inc.; Shareholders are Encouraged to Contact the Firm

Morris Kandinov Investigating CareDx, Inc., Puerto Rico Residents Tax-Free Fund, Inc., Puerto Rico Residents Tax-Free Fund VI, Inc., and Tax Free Fund.

SHAREHOLDER ALERT: Morris Kandinov Investigating CareDx, Inc., Puerto Rico Residents Tax-Free Fund, Inc., Puerto Rico Residents Tax-Free Fund VI, Inc., and Tax Free Fund for Puerto Rico Residents, Inc.; Shareholders are Encouraged to Contact the Firm

CareDx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA)- The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that, on September 12, 2024, CareDx granted an option to purchase 100,651 shares of CareDx's common stock (the “Kennedy Inducement Option”) and 70,101 restricted stock units (the “Kennedy Indu.

CareDx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CareDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that, as an inducement material to entering into employment with CareDx, on September 12, 2024, 14 new employees were awarded restricted stock units (RSUs) for an aggregate of 44,000 shares o.

CareDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CareDx Appoints Keith Kennedy Chief Operating Officer and Jessica Meng Chief Commercial Officer

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced the appointment of two senior executives who will lead key initiatives as the Company advances its long-term strategic growth plan. CareDx will be sharing its long-term growth strategy during an Investor Day in October 2024. Keith.

CareDx Appoints Keith Kennedy Chief Operating Officer and Jessica Meng Chief Commercial Officer

See News Rankings

Charts implemented using Lightweight Charts™